| Literature DB >> 25561328 |
Atsushi Miyachi1, Fumio Kondo2, Miki Kurita3, Kiyomi Tsuji4, Ken-ichi Harada3.
Abstract
The bacterial strain Sphingosinicella sp. B-9 was originally discovered to have the ability to degrade cyanobacterial cyclic peptides (microcystins), and has three hydrolytic enzymes (MlrA, MlrB, and MlrC). The purpose of this study was to examine in detail the degradation of glucagon/vasoactive intestinal polypeptide (VIP) family peptides by B-9, and to investigate the substrate specificity of B-9 proteases and the possibility of using a B-9 protease as a novel protease for peptide quantification by using a surrogate peptide and mass spectrometry (MS). The effective use of inhibitors revealed the following hydrolytic capability of B-9: One of the B-9 proteases (presumably MlrB) that was not inhibited by ethylenediaminetetraacetic acid (EDTA) cleaved bioactive peptides into medium-sized peptides with broad selectivity, similar to neutral endopeptidase, and another protease that was not inhibited by phenylmethylsulfonyl fluoride (PMSF) corresponded to MlrC and cleaved the resulting medium-sized peptides to smaller peptides or amino acids. The former property was desirable to obtain a suitable surrogate peptide, which was used successfully to quantify peptide using liquid chromatography (LC)-MS. Thus, the present study verified that one of the B-9 proteases has broad cleavage selectivity and cleavage sites, not seen in commercially available proteases, and is applicable to protein and peptide quantification using LC-MS.Entities:
Keywords: B-9 strain; Glucagon/vasoactive intestinal polypeptide family peptide; Inhibitor; Protease; Surrogate peptide
Mesh:
Substances:
Year: 2015 PMID: 25561328 DOI: 10.1016/j.jbiosc.2014.10.029
Source DB: PubMed Journal: J Biosci Bioeng ISSN: 1347-4421 Impact factor: 2.894